Pharmaceutical

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Mar 25, 2025 - 06:00
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.
Read the original article

Tags:

Previous Article

J&J boosts US operations with $55bn investment

Next Article

Revolutionary Nuclear Battery Promises Lifetime Power with Enhanced Safety

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In a showy hearing, Bernie Sanders gets few answers about lower drug prices

In a showy hearing, Bernie Sanders gets few answers abo...

Feb 9, 2024

STAT+: Wegovy may have another helpful trick: fighting inflammation via the brain, study finds

STAT+: Wegovy may have another helpful trick: fighting ...

Dec 19, 2023

Servier and Black Diamond sign deal for solid tumours therapy

Servier and Black Diamond sign deal for solid tumours t...

Mar 21, 2025